We scan new podcasts and send you the top 5 insights daily.
Even though CheckMate 274 showed improved disease-free survival in PD-L1-positive patients overall, oncologists caution against relying on PD-L1 to prescribe adjuvant nivolumab for upper tract tumors. Across urothelial cancer trials—including frontline metastatic settings—the PD-L1 biomarker has repeatedly failed to predict outcomes reliably. Furthermore, regulatory labels do not mandate PD-L1 testing, making it an unreliable surrogate for overcoming negative upper tract checkpoint inhibitor performance.
Contrary to its role in lung cancer, PD-L1 expression does not predict benefit from immunotherapy in mesothelioma. Data from major trials shows similar outcomes regardless of PD-L1 status, leading clinicians to omit this test entirely and streamline treatment decisions.
Early Phase 3 trials like JAVELIN adding immunotherapy to chemoradiation failed to improve outcomes. However, subgroup analyses consistently showed a potential benefit in PD-L1 high-expressing patients, a crucial lesson that informed the design of subsequent, more successful studies.
Despite broad approvals based on intent-to-treat populations, adjuvant immune checkpoint inhibitors have shown hazard ratios above 1.0 for both disease-free and overall survival in upper tract subsets across trials like CheckMate 274 (HR 1.23) and IMvigor010. Consequently, oncologists hesitate to extrapolate bladder cancer trial outcomes to upper tract disease, as dedicated evidence demonstrating a therapeutic benefit in this anatomical subgroup remains absent.
Some experts advocate for using immunotherapy in PD-L1 negative (CPS 0) gastric adenocarcinoma, arguing the biomarker test itself is unreliable. Factors like stromal sampling variability mean a "zero" score might not be truly negative, justifying treatment in a patient who would otherwise be excluded.
Data from the KEYNOTE-671 trial demonstrates a meaningful survival benefit from perioperative pembrolizumab even in patients with PD-L1 negative (<1%) tumors. This finding supported broad regulatory approval without PD-L1 restrictions, suggesting the biomarker is not an absolute requirement for benefit in this setting.
In adjuvant bladder cancer trials, ctDNA status is both prognostic and predictive. Patients with positive ctDNA after surgery are at high risk of relapse but benefit from immune checkpoint inhibitors. Conversely, ctDNA-negative patients have a lower risk and derive no benefit, making ctDNA a critical tool to avoid unnecessary, toxic therapy.
A PD-L1 CPS score of zero should not automatically disqualify patients with metastatic anal cancer from receiving immunotherapy. The clinical distinction between a CPS of zero and one is marginal, and given the therapy's potential for benefit and low toxicity, clinicians should give patients the benefit of the doubt and offer the treatment.
An expert argues forcefully that the PD-L1 biomarker should be "ditched" in bladder cancer. Citing its repeated failure to predict overall survival benefit across multiple major trials, it is deemed an oversimplified and unreliable tool that leads to both over- and under-treatment of patients.
Despite stratifying patients by PD-L1 status, the AGO-OV-229 trial found it was not a predictive marker. Hazard ratios for survival were similar for both PD-L1 positive and negative tumors, challenging its utility for patient selection.
Despite its use in other cancers, PD-L1 expression level is not used to guide immunotherapy decisions in the metastatic bladder cancer setting. Experts describe the correlation between PD-L1 status and patient outcomes as a "mess," making it clinically irrelevant for treatment selection in this disease.